{"id":745333,"date":"2016-09-07T05:45:00","date_gmt":"2016-09-07T05:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-assigns-priority-review-and-grants-breakthrough-therapy-designation-to-mercks-keytruda-pembrolizumab-for-first-line-treatment-o\/"},"modified":"2025-11-07T01:25:40","modified_gmt":"2025-11-07T06:25:40","slug":"fda-accepts-supplemental-biologics-license-application-assigns-priority-review-and-grants-breakthrough-therapy-designation-to-mercks-keytruda-pembrolizumab-for-first-line-treatment-o","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-assigns-priority-review-and-grants-breakthrough-therapy-designation-to-mercks-keytruda-pembrolizumab-for-first-line-treatment-o\/","title":{"rendered":"FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer"},"content":{"rendered":"<p class=\"bwalignc\">       Merck Has Also Submitted a Marketing Authorization Application to the        European Medicines Agency for KEYTRUDA in the Same Patient Population     <\/p>\n<p class=\"bwalignc\">       Submissions Based on Data from KEYNOTE-024 Trial Showing Superior        Progression-Free and Overall Survival Compared to Chemotherapy in        Patients Whose Tumors Express High Levels of PD-L1     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the U.S. Food and Drug Administration (FDA) has<br \/>\n      accepted for Priority Review the supplemental Biologics License<br \/>\n      Application (sBLA) for KEYTRUDA<sup>\u00ae <\/sup>(pembrolizumab), the<br \/>\n      company\u2019s anti-PD-1 therapy, for the first-line treatment of patients<br \/>\n      with advanced non-small cell lung cancer (NSCLC) whose tumors express<br \/>\n      PD-L1, with a PDUFA, or target action, date of Dec. 24, 2016.<br \/>\n      Additionally, the FDA granted Breakthrough Therapy Designation for this<br \/>\n      indication. Merck has also submitted a Marketing Authorization<br \/>\n      Application to the European Medicines Agency for this indication.\n    <\/p>\n<p>\n      The submissions were based on data from the pivotal phase 3 KEYNOTE-024<br \/>\n      study, which showed that KEYTRUDA monotherapy resulted in superior<br \/>\n      progression-free survival (PFS) as well as overall survival (OS)<br \/>\n      compared with standard chemotherapy in patients with advanced NSCLC<br \/>\n      whose tumors expressed high levels of PD-L1 (tumor proportion score of<br \/>\n      50 percent or more). Based on the results, the trial was stopped early<br \/>\n      to give patients still on chemotherapy the opportunity to receive<br \/>\n      KEYTRUDA. Merck filed for approval of KEYTRUDA in the first-line setting<br \/>\n      at a dose of 200 mg every three weeks, the dose studied in KEYNOTE-024.\n    <\/p>\n<p>\n      \u201cChemotherapy has been the foundation of first-line treatment for<br \/>\n      non-small cell lung cancer for decades, so the significant improvement<br \/>\n      in survival in patients with high PD-L1 expression seen with KEYTRUDA<br \/>\n      compared to chemotherapy is welcome news,\u201d said Dr. Roger M. Perlmutter,<br \/>\n      president, Merck Research Laboratories. \u201cWe appreciate the opportunity<br \/>\n      to work with regulatory authorities to make KEYTRUDA a first-line<br \/>\n      treatment option in non-small cell lung cancer.\u201d\n    <\/p>\n<p>\n      The FDA\u2019s Breakthrough Therapy Designation is intended to expedite the<br \/>\n      availability of promising new therapies that are planned for use, alone<br \/>\n      or in combination, to treat a serious or life-threatening disease or<br \/>\n      condition when preliminary clinical evidence indicates substantial<br \/>\n      improvement over existing therapies on one or more clinically<br \/>\n      significant endpoints. Merck previously announced that KEYTRUDA<br \/>\n      (pembrolizumab) was granted breakthrough status for specific patients<br \/>\n      with advanced melanoma, metastatic NSCLC in previously treated patients,<br \/>\n      microsatellite instability high metastatic colorectal cancer, and<br \/>\n      relapsed or refractory classical Hodgkin Lymphoma.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes<br \/>\n      every three weeks for the approved indications. KEYTRUDA for injection<br \/>\n      is supplied in a 100 mg single use vial.\n    <\/p>\n<p>\n      <b>KEYTRUDA Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a dose of 2 mg\/kg every three weeks.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with metastatic<br \/>\n      non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as<br \/>\n      determined by an FDA-approved test with disease progression on or after<br \/>\n      platinum-containing chemotherapy, at a dose of 2 mg\/kg every three<br \/>\n      weeks. Patients with EGFR or ALK genomic tumor aberrations should have<br \/>\n      disease progression on FDA-approved therapy for these aberrations prior<br \/>\n      to receiving KEYTRUDA (pembrolizumab). This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and durability of<br \/>\n      response. An improvement in survival or disease-related symptoms has not<br \/>\n      yet been established. Continued approval for this indication may be<br \/>\n      contingent upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. An sBLA is currently under review with the FDA for<br \/>\n      full approval of the existing second-line NSCLC indication. The<br \/>\n      application is based on data from KEYNOTE-010, a pivotal phase 2\/3<br \/>\n      confirmatory trial which demonstrated improved survival with KEYTRUDA<br \/>\n      compared to standard chemotherapy in previously treated patients with<br \/>\n      advanced NSCLC who had PD-L1 expression on one percent or more of the<br \/>\n      cancer cells. The FDA target action date is Oct. 24, 2016.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy at a fixed dose<br \/>\n      of 200 mg every three weeks. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and durability of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b><br \/>\n      (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      Immune-mediated pneumonitis occurred in 19 (3.5%) of 550 patients,<br \/>\n      including Grade 2 (1.1%), 3 (1.3%), 4 (0.4%), or 5 (0.2%) pneumonitis<br \/>\n      and occurred more frequently in patients with a history of<br \/>\n      asthma\/chronic obstructive pulmonary disease (5.4%) or prior thoracic<br \/>\n      radiation (6.0%). Monitor patients for signs and symptoms of<br \/>\n      pneumonitis. Evaluate suspected pneumonitis with radiographic imaging.<br \/>\n      Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold<br \/>\n      KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      Immune-mediated colitis occurred in 4 (0.7%) of 550 patients, including<br \/>\n      Grade 2 (0.2%) or 3 (0.4%) colitis. Monitor patients for signs and<br \/>\n      symptoms of colitis. Administer corticosteroids for Grade 2 or greater<br \/>\n      colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Immune-mediated hepatitis occurred in patients receiving KEYTRUDA.<br \/>\n      Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 1 (0.2%) of 550 patients, which was Grade 3 in<br \/>\n      severity. Monitor patients for signs and symptoms of hypophysitis<br \/>\n      (including hypopituitarism and adrenal insufficiency). Administer<br \/>\n      corticosteroids and hormone replacement as clinically indicated.<br \/>\n      Withhold KEYTRUDA (pembrolizumab) for Grade 2; withhold or discontinue<br \/>\n      for Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 10 (1.8%) of 550 patients, including Grade 2<br \/>\n      (0.7%) or 3 (0.3%) hyperthyroidism. Hypothyroidism occurred in 38 (6.9%)<br \/>\n      of 550 patients, including Grade 2 (5.5%) or 3 (0.2%) hypothyroidism.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 3<br \/>\n      (0.1%) of 2117 patients. Monitor patients for hyperglycemia or other<br \/>\n      signs and symptoms of diabetes. Administer insulin for type 1 diabetes,<br \/>\n      and withhold KEYTRUDA and administer anti-hyperglycemics in patients<br \/>\n      with severe hyperglycemia.\n    <\/p>\n<p>\n      Immune-mediated nephritis occurred in patients receiving KEYTRUDA.<br \/>\n      Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      Grade 3 immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of 550 patients: rash, vasculitis, hemolytic<br \/>\n      anemia, serum sickness, and myasthenia gravis.\n    <\/p>\n<p>\n      Severe and life-threatening infusion-related reactions have been<br \/>\n      reported in 3 (0.1%) of 2117 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA (pembrolizumab).\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 14% of 550<br \/>\n      patients. Serious adverse reactions occurred in 38% of patients. The<br \/>\n      most frequent serious adverse reactions reported in at least 2% of<br \/>\n      patients were pleural effusion, pneumonia, dyspnea, pulmonary embolism<br \/>\n      and pneumonitis. The most common adverse reactions (reported in at least<br \/>\n      20% of patients) were fatigue (44%), cough (29%), decreased appetite<br \/>\n      (25%), and dyspnea (23%).\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment. Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 330 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51414766&amp;newsitemid=20160907005223&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=fc1661c7e789ee76a4fada88a714276d\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51414766&amp;newsitemid=20160907005223&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=508879ade1a712914ba540778a1752cd\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51414766&amp;newsitemid=20160907005223&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=2cc5af9bf74f894a82330344463cf3f6\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51414766&amp;newsitemid=20160907005223&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=f4d3c12e544bdc59f4130fe493b2a605\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51414766&amp;newsitemid=20160907005223&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=a35631fa34290ccc6940ccbed5ba402e\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51414766&amp;newsitemid=20160907005223&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=ad1daa3f94e311936b3cf3fb8dc7d3d5\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51414766&amp;newsitemid=20160907005223&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=96eab88092fb22fd15447a338d4f9293\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51414766&amp;newsitemid=20160907005223&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=fb1f3c921f9815191b7f55bcd4549246\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51414766&amp;newsitemid=20160907005223&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=4339719e9bbedb0488558ca586ae2a27\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160907005223r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Courtney        Ronaldo, 908-236-1108<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1, with a PDUFA, or target action, date of Dec. 24, 2016. Additionally, the FDA granted Breakthrough Therapy Designation for this indication. Merck has also submitted a Marketing Authorization Application to the European Medicines Agency for this indication. The submissions were based on data from the pivotal phase 3 KEYNOTE-024 study, which showed that KEYTRUDA monotherapy resulted in superior progression-free survival (PFS) as well as overall survival (OS) compared with standard chemotherapy in patients with advanced NSCLC whose tumors expressed high levels of PD-L1 (tumor proportion score<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289],"class_list":["post-745333","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-assigns-priority-review-and-grants-breakthrough-therapy-designation-to-mercks-keytruda-pembrolizumab-for-first-line-treatment-o\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1, with a PDUFA, or target action, date of Dec. 24, 2016. Additionally, the FDA granted Breakthrough Therapy Designation for this indication. Merck has also submitted a Marketing Authorization Application to the European Medicines Agency for this indication. The submissions were based on data from the pivotal phase 3 KEYNOTE-024 study, which showed that KEYTRUDA monotherapy resulted in superior progression-free survival (PFS) as well as overall survival (OS) compared with standard chemotherapy in patients with advanced NSCLC whose tumors expressed high levels of PD-L1 (tumor proportion score\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-assigns-priority-review-and-grants-breakthrough-therapy-designation-to-mercks-keytruda-pembrolizumab-for-first-line-treatment-o\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-supplemental-biologics-license-application-assigns-priority-review-and-grants-breakthrough-therapy-designation-to-mercks-keytruda-pembrolizumab-for-first-line-treatment-o\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-supplemental-biologics-license-application-assigns-priority-review-and-grants-breakthrough-therapy-designation-to-mercks-keytruda-pembrolizumab-for-first-line-treatment-o\\\/\",\"name\":\"FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-09-07T05:45:00+00:00\",\"dateModified\":\"2025-11-07T06:25:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-supplemental-biologics-license-application-assigns-priority-review-and-grants-breakthrough-therapy-designation-to-mercks-keytruda-pembrolizumab-for-first-line-treatment-o\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-supplemental-biologics-license-application-assigns-priority-review-and-grants-breakthrough-therapy-designation-to-mercks-keytruda-pembrolizumab-for-first-line-treatment-o\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-supplemental-biologics-license-application-assigns-priority-review-and-grants-breakthrough-therapy-designation-to-mercks-keytruda-pembrolizumab-for-first-line-treatment-o\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-assigns-priority-review-and-grants-breakthrough-therapy-designation-to-mercks-keytruda-pembrolizumab-for-first-line-treatment-o\/","og_locale":"en_US","og_type":"article","og_title":"FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1, with a PDUFA, or target action, date of Dec. 24, 2016. Additionally, the FDA granted Breakthrough Therapy Designation for this indication. Merck has also submitted a Marketing Authorization Application to the European Medicines Agency for this indication. The submissions were based on data from the pivotal phase 3 KEYNOTE-024 study, which showed that KEYTRUDA monotherapy resulted in superior progression-free survival (PFS) as well as overall survival (OS) compared with standard chemotherapy in patients with advanced NSCLC whose tumors expressed high levels of PD-L1 (tumor proportion score","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-assigns-priority-review-and-grants-breakthrough-therapy-designation-to-mercks-keytruda-pembrolizumab-for-first-line-treatment-o\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:40+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-assigns-priority-review-and-grants-breakthrough-therapy-designation-to-mercks-keytruda-pembrolizumab-for-first-line-treatment-o\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-assigns-priority-review-and-grants-breakthrough-therapy-designation-to-mercks-keytruda-pembrolizumab-for-first-line-treatment-o\/","name":"FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-09-07T05:45:00+00:00","dateModified":"2025-11-07T06:25:40+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-assigns-priority-review-and-grants-breakthrough-therapy-designation-to-mercks-keytruda-pembrolizumab-for-first-line-treatment-o\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-assigns-priority-review-and-grants-breakthrough-therapy-designation-to-mercks-keytruda-pembrolizumab-for-first-line-treatment-o\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-supplemental-biologics-license-application-assigns-priority-review-and-grants-breakthrough-therapy-designation-to-mercks-keytruda-pembrolizumab-for-first-line-treatment-o\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"aa66aa9b-0a34-48db-9515-36ba1da7284f","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/FDA-Accepts-Supplemental-Biologics-License-Application-Assigns-Priority-Review-and-Grants-Breakthrough-Therapy-Designation-to-Mercks--U6T2Y.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745333\/revisions"}],"predecessor-version":[{"id":3674740,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745333\/revisions\/3674740"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745333"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}